Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054464 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants
A Phase 1 study, sponsored by PMV Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT06054464 is a Phase 1 study that has completed, run by PMV Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT06054464, a Phase 1 study, has completed, sponsored by PMV Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will assess the effect of a Proton Pump Inhibitor (PPI) (rabeprazole) on the pharmacokinetics (PK) of PC14586 and the effect of an H2-receptor antagonist (famotidine) on the PK of PC14586
Interventions
- DRUG Rabeprazole
- DRUG Famotidine
- DRUG PC14586
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2024-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06054464
The ClinicalTrials.gov registry entry for NCT06054464 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PMV Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rabeprazole is the first listed.
NCT06054464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06054464 about?
NCT06054464 is a clinical study titled "A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants". This study will assess the effect of a Proton Pump Inhibitor (PPI) (rabeprazole) on the pharmacokinetics (PK) of PC14586 and the effect of an H2-receptor antagonist (famotidine) on the PK of PC14586
What is the current status of trial NCT06054464?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-09-19. Estimated completion is 2024-02-06.
What interventions are being tested in trial NCT06054464?
The interventions under investigation include: Rabeprazole (DRUG), Famotidine (DRUG), PC14586 (DRUG).
Who is sponsoring clinical trial NCT06054464?
This trial is sponsored by PMV Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.